Entera Bio (ENTX) Change in Receivables (2021 - 2024)

Entera Bio (ENTX) has reported Change in Receivables for 4 consecutive years, with -$7000.0 the latest figure, recorded in Q4 2024.

• Quarterly Change in Receivables changed N/A year-over-year to -$7000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $69000.0 (down 45.24% YoY) and the FY2025 annual result came in at -$126000.0, down 200.0% from the prior year.
• Change in Receivables retreated to -$7000.0 in Q4 2024 per ENTX's latest filing, from $76000.0 in the prior quarter.
• Over the last five years, Change in Receivables for ENTX reached as high as $136000.0 in Q3 2021 and fell as low as -$240000.0 in Q1 2021.
• A 4-year average of -$9923.1 and a median of $13000.0 in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2023 — Change in Receivables tumbled 903.7% — and 2024, when it surged 362.07%.
• Year by year, Change in Receivables stood at -$69000.0 in 2021, then soared by 118.84% to $13000.0 in 2022, then tumbled by 323.08% to -$29000.0 in 2023, then jumped by 75.86% to -$7000.0 in 2024.
• According to Business Quant data, Change in Receivables over the past three periods registered -$7000.0, $76000.0, and $57000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.